Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CTSV | O60911 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18469462 | 0.94 | MAPT (0.30) | MAPT | |
| SCHEMBL16854586 | 0.89 | MAPT (0.34) | MAPTCHRM3CYP3A4TSHRCTSV | |
| SCHEMBL19174733 | 0.89 | MAPT (0.34) | MAPTCHRM3CYP3A4TSHRCTSV | |
| SCHEMBL30530221 | 0.84 | MAPT (0.34) | MAPTCHRM3CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL19174735 | 0.83 | CTSK (0.36) | MAPTCHRM3CYP3A4TSHRCTSV | |
| SCHEMBL16869844 | 0.79 | CNR1 (0.32) | — | |
| SCHEMBL16819025 | 0.78 | CNR2 (0.31) | — | |
| SCHEMBL16819024 | 0.78 | CNR2 (0.31) | — | |
| SCHEMBL19174759 | 0.71 | ALDH1A1 (0.33) | ATML3MBTL1ALDH1A1 | |
| SCHEMBL1260916 | 0.69 | CNR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030033-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170267694-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030033-B2 | Synthesis of an antiviral compound | EIF2AK2, MAVS, SARS1 | MAPT 4619/4885CHRM3 4819/4885CYP3A4 652/4885 |
| US-20170267694-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | HAVCR2, IFNAR1, ZC3HAV1 | MAPT 2270/4885CHRM3 3802/4885CYP3A4 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.